Sugi Predict

Sugi Predict / Compounds / SCHEMBL143924

SCHEMBL143924

SCHEMBL143924

CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.79
▸ LMNA P02545 5/20 0.79
▸ SERPINA6 P08185 5/20 0.79
▸ NR3C1 P04150 4/20 0.79
▸ SMN1; SMN2 Q16637 4/20 0.79
▸ SHBG P04278 4/20 0.79
▸ TSHR P16473 3/20 0.79
▸ CYP3A4 P08684 2/20 0.79
▸ PMP22 Q01453 2/20 0.79
▸ ALDH1A1 P00352 2/20 0.79
▸ CYP2D6 P10635 1/20 0.79
▸ KCNA1 Q09470 1/20 0.79
▸ SLC47A1 Q96FL8 1/20 0.79
▸ FNTA P49354 5/20 0.75
▸ FNTB P49356 5/20 0.75
▸ BLM P54132 3/20 0.75
▸ MEN1 O00255 2/20 0.75
▸ KMT2A Q03164 2/20 0.75
▸ AR P10275 1/20 0.75
▸ CYP2C19 P33261 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11885536 1.00 HSD17B10 (0.79) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
SCHEMBL19327145 1.00 HSD17B10 (0.79) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
Hydroxyprogesterone SCHEMBL19327144 0.95 LMNA (0.82) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
SCHEMBL1625974 0.91 HSD17B10 (0.79) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
SCHEMBL1625973 0.91 HSD17B10 (0.79) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
SCHEMBL11615772 0.89 HSD17B10 (0.76) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
SCHEMBL20243021 0.89 HSD17B10 (0.75) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
Cortisone SCHEMBL4888 0.89 HSD17B10 (1.00) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
Cortisone SCHEMBL13332835 0.89 HSD17B10 (1.00) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2
Cortisone SCHEMBL9926754 0.89 HSD17B10 (1.00) HSD17B10LMNASERPINA6NR3C1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250041208-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2025-02-06 — — US claimed
CN-118858479-A Kit for simultaneously detecting 90 steroid hormones and metabolites thereof in urine sample, detection method and sample pretreatment method 中国疾病预防控制中心环境与健康相关产品安全所 2024-10-29 — — CN claimed
EP-4444277-A1 NEW INJECTABLE COMBINATION FORMULATION Nanexa AB (SE) 2024-10-16 — — EP claimed
CN-118647367-A Novel injectable combination formulations 南爱克萨股份公司 2024-09-13 — — CN claimed
WO-2023105227-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2023-06-15 — — WO claimed
CN-115920222-A Microneedle and preparation method thereof, microneedle patch and preparation method thereof 成都柔电云科科技有限公司 2023-04-07 — — CN claimed
WO-2023005973-A1 USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT 中国医学科学院基础医学研究所 2023-02-02 — — WO claimed
US-20210386712-A1 NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST VICORE PHARMA AB (SE) 2021-12-16 — — US claimed
US-10088490-B2 Assay for analytes using multiple receptors SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2018-10-02 — — US claimed
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS ZALICUS INC. (US) 2012-03-08 — — US claimed
US-20120028910-A1 STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS FOVEA PHARMACEUTICALS (FR) 2012-02-02 — — US claimed
US-8080553-B2 Methods and reagents for the treatment of immunoinflammatory disorders ZALICUS INC. (US) 2011-12-20 — — US claimed
EP-2301628-A1 Methods and reagents for the treatment of immunoinflammatory disorders Zalicus Inc. (US) 2011-03-30 — — EP claimed
EP-2070550-A1 Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases Combinatorx, Incorporated (US) 2009-06-17 — — EP claimed
US-20070010502-A1 Methods and reagents for the treatment of immunoinflammatory disorders COMBINATORX INC. (US) 2007-01-11 — — US claimed
WO-1997038015-A1 ARTIFICIAL ANTIBODIES TO CORTICOSTEROIDS PREPARED BY MOLECULAR IMPRINTING IGEN, INC. (US) 1997-10-16 — — WO claimed
CN-122028898-A Novel short-chain peptides and derivatives thereof 艾缇亚(上海)制药有限公司 2026-05-12 — — CN disclosed
US-20260124244-A1 MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES STELLULAR BIO, INC. (US) 2026-05-07 — — US disclosed
US-4501701-A 20-Isocyano-Δ17(20) -steroids ROUSSEL UCLAF (FR) 1985-02-26 — — US disclosed
US-4329294-A Process for preparing 17α-hydroxy-20-ketosteroids EASTMAN KODAK COMPANY (US) 1982-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010502-A1 Methods and reagents for the treatment of immunoinflammatory disorders IL5, TPMT, TSLP HSD17B10 2384/4885LMNA 3888/4885SERPINA6 12/4885
US-20260124244-A1 MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES MYH10, PDGFA, MPL HSD17B10 4379/4885LMNA 1063/4885SERPINA6 894/4885
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS IL5, TPMT, TSLP HSD17B10 2384/4885LMNA 3888/4885SERPINA6 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.